TRDAHealthcare · BiotechnologyThe 8 Wall Street analysts covering Entrada Therapeutics, Inc. hold a median 12-month price target of $20 — +354.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 29 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Entrada Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (80): Reported profit is backed by cash, and the company is not expanding recklessly.
Value (21): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TRDA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +354.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 8 June 2026 | Guggenheim | Maintains | Buy | $20 → $17 |
| 8 May 2026 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 6 Apr 2026 | Oppenheimer | Maintains | Outperform | — |
| 18 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 Feb 2026 | Guggenheim | Initiates | Buy | — |
| 20 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 31 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Dec 2024 | Roth MKM | Initiates | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Nov 2024 | Oppenheimer | Maintains | Outperform | — |
| 26 Aug 2024 | Oppenheimer | Reiterates | Outperform | — |
| 14 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 June 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Jan 2024 | Oppenheimer | Initiates | Outperform | — |
| 27 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Sept 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TRDA appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Entrada Therapeutics, Inc. returned −36.1% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 58% of US stocks
Cheaper than 6% of US stocks
Cheaper than 78% of US stocks
Cheaper than 62% of US stocks
Higher than 5% of US stocks
Higher than 9% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 21% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Entrada Therapeutics, Inc. has a market value of $188.5M and an enterprise value of $55K.
Revenue in the twelve months to 30 June 2026: $4.7M. The latest quarter shrank 53.9% year on year.
Net income over the same four quarters: −$165.8M, a −3537.7% net margin.
Diluted earnings per share, trailing twelve months: $−3.96.
Free cash flow in the twelve months to 30 June 2026: −$134.4M.
Trailing P/E: 10.1×; forward P/E: −1.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Entrada Therapeutics, Inc. employs 152 people — $31K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Entrada Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Entrada Therapeutics announced the appointment of Linea Aspesi as Chief People Officer. CEO Dipal Doshi cited her experience scaling organizations and developing teams across discovery and commercial stages.
Why it matters — TRDA watchers may note the leadership appointment and Aspesi’s stated experience building teams across company stages.
An independent Data Monitoring Committee reviewed available safety and pharmacokinetic data from the eight participants in Cohort 2 of ELEVATE-44-201 and recommended starting Cohort 3 at 18 mg/kg. The company said Cohort 2 enrollment is complete, with data expected in Q1 2027, and Cohort 1 open-label data expected by year-end 2026.
Why it matters — The recommendation advances dose escalation in the study, while the stated data timelines provide updates on when results may be available.
Entrada Therapeutics reported Cohort 1 results from its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in participants with Duchenne muscular dystrophy. At 5 mg/kg, the cohort met primary safety and tolerability objectives; mean dystrophin increased 0.10% versus baseline, and plasma exposures were consistent with predictions from juvenile non-human primate data.
Why it matters — The update provides early safety and biomarker data for ENTR-601-45, while Cohort 2 at 10 mg/kg is fully enrolled and data are expected in the first half of 2027.
A Seeking Alpha article rates Entrada Therapeutics Buy, citing potential validation of its EEV platform and a plausible explanation for disappointing initial ENTR-601-44 dystrophin data: lower drug exposure in children. It notes higher-dose results are expected in Q1 2027 and discusses pipeline-based valuation and cash reserves.
Why it matters — TRDA watchers may focus on whether higher dosing produces stronger dystrophin results, a key test of the article’s explanation and platform thesis.
Entrada Therapeutics announced the recipients of its 2026 DREAMS Grant Program, a competitive annual initiative awarding two $50,000 grants to projects that help identify, understand, and reach underrepresented or underserved members of the Duchenne muscular dystrophy community. The announcement followed World Duchenne Awareness Day on September 7.
Why it matters — TRDA watchers would note that the company is investing in community outreach and awareness efforts within the Duchenne muscular dystrophy space, reinforcing its engagement with the patient population central to its therapeutic focus.
The 8 Wall Street analysts covering Entrada Therapeutics, Inc. have a median 12-month price target of $20, with estimates ranging from $11 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Entrada Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Entrada Therapeutics, Inc. 50 out of 100 across roughly 4,600 US stocks as at 29 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 29 Oct 2026, Entrada Therapeutics, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (80 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +354.5% from the last close, and Ticker Nerd's factor model ranks Entrada Therapeutics, Inc. 50 out of 100 as at 29 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Entrada Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRDA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $25 over the next 12 months.
Entrada Therapeutics, Inc. returned -36.1% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing intracellular therapeutics that are designed to reach targets inside cells that have traditionally been difficult to address.
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer". Entrada Therapeutics announced the appointment of Linea Aspesi as Chief People Officer. CEO Dipal Doshi cited her experience scaling organizations and developing teams across discovery and commercial stages.
Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing intracellular therapeutics that are designed to reach targets inside cells that have traditionally been difficult to address. Its proprietary Endosomal Escape Vehicle platform supports the delivery of genetic medicine candidates and other therapeutic modalities across multiple tissues, with a current emphasis on neuromuscular and inherited retinal diseases. The company’s pipeline includes programs in development for rare and severe conditions, reflecting its role in advancing novel drug-delivery approaches in biotechnology. Entrada Therapeutics, Inc. is headquartered in Boston, Massachusetts, and operates as a development-stage company centered on research, clinical development, and platform-driven innovation in precision medicine.
CEO Mr. Dipal Doshi · 152 employees · United States · https://www.entradatx.com
